CM Life Sciences, Inc.
CMLFU
NASDAQ Capital Market13.00
USD
-0.62
- -
CIK
0001818331
ISIN
US18978W2089
CUSIP
18978W208
Return %
Stock
S&P500
1Y
- -
18.46
3Y
26.83
64.72
5Y
26.83
72.79
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Eli Decatur Casdin
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 667 Madison Avenue New York City NY United States of America
- IPO Date
- Sep 2, 2020
- CIK
- 0001818331
- Website
- i.cmlifesciencesspac.com
- Similar Companies
- Business
- CM Life Sciences, Inc. is a special purpose acquisition company (SPAC) focused on the life sciences sector, targeting innovative companies within areas such as life sciences tools, synthetic biology, and diagnostics. The company operates with a strategic approach to invest in and consolidate fragmented life science businesses that are under-resourced and under-scaled. CM Life Sciences leverages deep sector expertise and strong industry relationships to drive growth and operational improvements in its portfolio companies. Its core activities include identifying and acquiring companies with regulated products and services that support drug discovery, development, manufacturing, and provide high-value tools for research and development across academia, government, and industry. The company was founded in 2020 and is headquartered in New York, New York. Its management team is led by CEO Eli D. Casdin. A major recent development is CM Life Sciences' business combination with Sema4, a patient-centered health intelligence company leveraging AI and machine learning to generate genomic and clinical data insights. This significant merger, completed in 2021, positioned Sema4 as a publicly traded company on Nasdaq under the CM Life Sciences listing. The deal was valued at approximately $2 billion and included a private investment in public equity (PIPE) financing, enabling CM Life Sciences/Sema4 to accelerate growth in precision medicine solutions. This merger also marked a strategic expansion into AI-driven genomic and clinical data platforms aiming to transform clinical and life sciences through data innovation. Additionally, CM Life Sciences has engaged in other transactions in the life sciences space, including the acquisition of SomaLogic, a protein biomarker discovery and diagnostics company, enhancing its footprint in diagnostics and biomarker technology. The company's investment scope spans tools and services essential for R&D workflows, and it continues to build out a portfolio focused on innovative and scalable life sciences enterprises across the US and Canada. CM Life Sciences is sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, which bring operational expertise and investment acumen to its business model. Thus, CM Life Sciences operates primarily by acquiring and growing companies that provide regulated products and services in life sciences tools, synthetic biology, diagnostics, and health intelligence, with a key recent transformation driven by its merger with Sema4 and other strategic acquisitions in the sector. It targets customers across biopharmaceutical, healthcare, and research markets with offerings that span genomic testing, clinical data platforms, and biomarker discovery technologies. Its main operations are concentrated in North America, with emphasis on innovation-driven life sciences companies founded around or after 2020. This consolidated portfolio approach is designed to capture synergies and deliver long-term value through active management and capital deployment in the life sciences domain. CM Life Sciences remains a critical player for investors targeting growth via life science innovation focused on precision diagnostic and therapeutic platforms.